Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
581 to 600 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Clinical applications of gene therapy for rare diseases: A review. | Int J Exp Pathol | 2023 | 37177842 | PubTator, text mining | PubMed |
| Gaps and complex structurally variant loci in phased genome assemblies. | Genome Res | 2023 | 37164484 | PubTator, text mining | PubMed |
| Tudor-dimethylarginine interactions: the condensed version. | Trends Biochem Sci | 2023 | 37156649 | PubTator, text mining | PubMed |
| The regulatory role of alternative splicing in inflammatory bowel disease. | Front Immunol | 2023 | 37153612 | PubTator, text mining | PubMed |
| Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience. | Pediatr Neurol | 2023 | 37149951 | PubTator, text mining | PubMed |
| Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching. | Nat Commun | 2023 | 37149717 | PubTator, text mining | PubMed |
| Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children. | Clin Pharmacokinet | 2023 | 37148485 | PubTator, text mining | PubMed |
| Objective measurement of oral function in adults with spinal muscular atrophy. | Orphanet J Rare Dis | 2023 | 37138365 | PubTator, text mining | PubMed |
| Brain Magnetic Resonance Imaging (MRI) in Spinal Muscular Atrophy: A Scoping Review. | J Neuromuscul Dis | 2023 | 37125560 | PubTator, text mining | PubMed |
| A QSAR study to predict the survival motor neuron promoter activity of candidate diaminoquinazoline derivatives for the potential treatment of spinal muscular atrophy. | SAR QSAR Environ Res | 2023 | 37125536 | PubTator, text mining | PubMed |
| Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data. | J Clin Med | 2023 | 37109175 | PubTator, text mining | PubMed |
| Redox Imbalance in Neurological Disorders in Adults and Children. | Antioxidants (Basel) | 2023 | 37107340 | PubTator, text mining | PubMed |
| Longitudinal prospective cohort study to assess peripheral motor function with extensive electrophysiological techniques in patients with Spinal Muscular Atrophy (SMA): the SMA Motor Map protocol. | BMC Neurol | 2023 | 37095427 | PubTator, text mining | PubMed |
| Implementation of Newborn Screening for Conditions in the United States First Recommended during 2010-2018. | Int J Neonatal Screen | 2023 | 37092514 | PubTator, text mining | PubMed |
| Gene therapy for spinal muscular atrophy is considerably effective when administered as early as possible after birth. | Mol Genet Metab Rep | 2023 | 37091744 | PubTator, text mining | PubMed |
| Flail arm syndrome due to duplication mutations in the SMN1 gene: A case report. | Medicine (Baltimore) | 2023 | 37083780 | PubTator, text mining | PubMed |
| Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study. | Brain Behav | 2023 | 37070132 | PubTator, text mining | PubMed |
| Improvement of muscle strength in specific muscular regions in nusinersen-treated adult patients with 5q-spinal muscular atrophy. | Sci Rep | 2023 | 37069197 | PubTator, text mining | PubMed |
| New therapies for spinal muscular atrophy: where we stand and what is next. | Eur J Pediatr | 2023 | 37067602 | PubTator, text mining | PubMed |
| Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma). | Cureus | 2023 | 37065340 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=30